Tenaya Therapeutics Unveils Interim Data from MyClimb™ Study at ESC 2025, Offering New Insights into Pediatric MYBPC3-associated HCM Risks
Reuters
Aug 31, 2025
Tenaya <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Interim Data from MyClimb™ Study at ESC 2025, Offering New Insights into Pediatric MYBPC3-associated HCM Risks
Tenaya Therapeutics Inc. has announced the presentation of interim data from its ongoing MyClimb™ natural history study at the European Society of Cardiology Congress 2025. The study focuses on pediatric participants with MYBPC3-associated hypertrophic cardiomyopathy $(HCM)$, marking it as the largest noninterventional natural history study of individuals under 18 with this condition. The interim findings reveal that 93% of participants have the nonobstructive form of HCM, for which there are currently no approved therapeutics. Key observations from the study indicate that genotypic status is a significant predictor of risk, and a higher left ventricular mass index may serve as a surrogate marker for poor long-term outcomes. These insights could influence future risk stratification and intervention strategies, as well as inform clinical trial endpoints and eligibility criteria for potential genetic treatments like TN-201 gene therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520776-en) on August 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.